Known targets — ChEMBL curated mechanism
ADRB1CDK4CDK6CHRM2CHRM3DPP4DRD2DRD3DRD4EGFRHRH1HTR1BHTR1DHTR1FHTR2AHTR2CHTR4SLC6A2SLC6A4
The experimentally established mechanism targets of Succinic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 known ✓ | Q13639 | 15/20 | 0.47 |
| ▸ | ACHE | P22303 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2332701 | 0.96 | HTR4 (0.51) | HTR4ACHECYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL5631883 | 0.95 | HTR4 (0.50) | HTR4ACHECYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL5332277 | 0.90 | HTR4 (0.47) | HTR4ACHE | |
| SCHEMBL5630511 | 0.86 | HTR4 (0.45) | HTR4ACHECYP3A4CYP2D6 | |
| SCHEMBL8230449 | 0.85 | HTR4 (0.49) | HTR4ACHECYP3A4CYP2D6 | |
| SCHEMBL17978168 | 0.84 | HTR4 (0.46) | HTR4ACHECYP3A4CYP2D6 | |
| SCHEMBL14382457 | 0.82 | HTR4 (0.44) | HTR4ACHE | |
| SCHEMBL17978225 | 0.81 | HTR4 (0.44) | HTR4ACHE | |
| Cadaverine Tartrate SCHEMBL20968901 | 0.81 | HTR4 (0.44) | HTR4ACHECYP3A4CYP2D6 | |
| SCHEMBL2331750 | 0.81 | HTR4 (0.53) | HTR4ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232657-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232657-A1 | NOVEL COMPOUNDS | HTR4, HTR5A, HTR6 | HTR4 1/4885ACHE 306/4885CYP3A4 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.